Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.59 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 6/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5174667 | 0.87 | SIGMAR1 (0.65) | SIGMAR1DRD4LTA4HCXCR3POLB | |
| SCHEMBL5174319 | 0.82 | SIGMAR1 (0.64) | SIGMAR1DRD4LTA4HCXCR3POLB | |
| SCHEMBL5174634 | 0.81 | LTA4H (0.65) | SIGMAR1LTA4HPOLB | |
| SCHEMBL5175866 | 0.81 | LTA4H (0.46) | SIGMAR1LTA4HKCNH2 | |
| SCHEMBL5176090 | 0.79 | POLB (0.67) | SIGMAR1LTA4HPOLBKCNH2 | |
| SCHEMBL5175714 | 0.76 | LTA4H (0.64) | SIGMAR1DRD4LTA4HPOLB | |
| SCHEMBL5173761 | 0.76 | LTA4H (0.52) | SIGMAR1LTA4H | |
| SCHEMBL5174906 | 0.75 | MCHR1 (0.61) | SIGMAR1LTA4HPOLBKCNH2CD274 | |
| SCHEMBL5504017 | 0.75 | SIGMAR1 (0.82) | SIGMAR1DRD4CXCR3 | |
| SCHEMBL5175775 | 0.74 | LTA4H (0.56) | SIGMAR1LTA4HKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1868605-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-26 | — | — | EP | claimed |
| WO-2006105304-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | claimed |
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | claimed |
| EP-1868605-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006105304-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | disclosed |
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | LTA4H, LTB4R, LTC4S | SIGMAR1 3624/4885DRD4 3772/4885LTA4H 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.